Notes: GLP-1s Cut Bariatric Surgery 34%

GLP-1 use rose more than 140% from 2022 to 2024 while bariatric surgery volumes fell 34.1%, per new JAMA Surgery article. Classic Demand Elimination — and more than 90% of eligible patients still received neither treatment.